Form 13-F position report

IRONWOOD PHARMACEUTICALS IN

Reported by CAPSTONE INVESTMENT ADVISORS LLC

IRWD 0.75 06/15/24 CUSIP 46333XAF5 Manager CIK 0001426196

Reported 17,700,000 shares, up 5,000,000 (39.4%) from the prior quarter.

Reported value 27.7%; share count 39.4% vs. the prior quarter.

Added
% of reported 13F value 0.09% This manager · Q2 2022
Shares 17,700,000 Quarter-end amount reported
Reported value $18,674,000 Fair value at quarter end
Consecutive quarters held 8 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 10870000
2022-03-31 14624000
2022-06-30 18674000
2022-09-30 22913000
2022-12-31 24473438
2023-03-31 32589833
2023-06-30 40617120
2023-09-30 39922620
2023-12-31 50204252
2024-03-31 51538438
2024-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for IRONWOOD PHARMACEUTICALS IN held by CAPSTONE INVESTMENT ADVISORS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2024 Unchanged 0 0 (0.0%) 0 $0 2024-08-14
Q1 2024 Unchanged 0 0 (0.0%) 0.19% $51,538,438 2024-05-01
Q4 2023 Reduced 0 -40,200,000 (-100.0%) 0.15% $50,204,252 2024-02-12
Q3 2023 Unchanged 40,200,000 0 (0.0%) 0.18% $39,922,620 2023-11-13
Q2 2023 Added 40,200,000 +8,000,000 (24.8%) 0.2% $40,617,120 2023-08-10
Q1 2023 Added 32,200,000 +9,500,000 (41.9%) 0.16% $32,589,833 2023-05-09
Q4 2022 Unchanged 22,700,000 0 (0.0%) 0.18% $24,473,438 2023-02-10
Q3 2022 Added 22,700,000 +5,000,000 (28.2%) 0.14% $22,913,000 2022-11-10
Q2 2022 Added 17,700,000 +5,000,000 (39.4%) 0.09% $18,674,000 2022-08-15
Q1 2022 Added 12,700,000 +3,000,000 (30.9%) 0.04% $14,624,000 2022-05-13
Q4 2021 Unchanged 9,700,000 0 (0.0%) 0.02% $10,870,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

24 managers reported IRONWOOD PHARMACEUTICALS IN for Q2 2022.

Managers reporting IRONWOOD PHARMACEUTICALS IN in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
CITADEL ADVISORS LLC Added 93,100,000 +3,000,000 0.03% $98,152,000 8 qtrs
WOLVERINE ASSET MANAGEMENT LLC Unchanged 0 0 0.29% $29,301,000 8 qtrs
CAPSTONE INVESTMENT ADVISORS LLC This report Added 17,700,000 +5,000,000 0.09% $18,674,000 8 qtrs
TENOR CAPITAL MANAGEMENT Co L P Added 14,416,000 +4,000,000 0.34% $15,218,000 8 qtrs
SHENKMAN CAPITAL MANAGEMENT INC Added 11,052,000 +7,089,000 0.69% $11,459,000 8 qtrs
Jefferies Group LLC Added 10,096,000 +3,169,000 0.09% $10,674,524 8 qtrs
Calamos Advisors LLC Unchanged 7,500 0 0.03% $7,910,000 8 qtrs
AQR Arbitrage LLC Unchanged 5,200,000 0 0.12% $5,486,000 8 qtrs
Daiwa Securities Group Inc New 5,000,000 +5,000,000 0.04% $5,261,000 3 qtrs
ABSOLUTE INVESTMENT ADVISERS LLC New 3,500,000 +3,500,000 0.73% $3,675,000 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
NOTE 0.750% 6/1

Voting authority reported

Sole
17,700,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.